Page 43 - วารสารกรมการแพทย์แผนไทยฯ ปีที่ 14 ฉบับที่ 3
P. 43
261
μ“√“ß∑’Ë 2 ¬“√—°…“‚√§∑“ß®‘쇫™∑’˺à“π°“√√—∫√Õß®“° ”π—°ß“πÕ“À“√·≈–¬“¢Õß À√—∞Õ‡¡√‘°“ (US Food and Drug
Administration: FDA)
[4]
∑’Ë¡“: ¥—¥·ª≈ßμ“√“ß¡“®“° Hoffman and Mathew (2008)
Õ—°…√¬àÕ: GAD, ‚√§«‘μ°°—ß«≈∑—Ë«‰ª; PD, ‚√§·æπ‘°; PTSD, ‚√§‡§√’¬¥À≈—߇º™‘≠‡Àμÿ√⓬; PB, ‚√§°≈—«; OCD, ‚√§¬È”§‘¥¬È”∑”;
AD, ‚√§´÷¡‡»√â“∑’ˇªìπ√à«¡°—∫‚√§«‘μ°°—ß«≈; MDD, ‚√§´÷¡‡»√â“Õ¬à“ß√ÿπ·√ß; PMDD, ‚√§‡§√’¬¥°àÕπ¡’ª√–®”‡¥◊Õπ;
STA, ‚√§«‘μ°°—ß«≈„π√–¬– —Èπ Ê; ETOHw, ‚√§¢“¥ ÿ√“; Insomnia, ‚√§πÕπ‰¡àÀ≈—∫
¬—ß “¡“√∂π—∫Õ¬Ÿà„π‡°≥±å¡“μ√∞“π¢Õß°“√ √â“ß ´àÕπ À≈’°Àπ’ ·≈–À¬ÿ¥π‘Ëß°—∫∑’ˇæ◊ËÕª√–‡¡‘π
[6]
·∫∫®”≈Õß„π —μ«å∑¥≈Õ߉¥â ∂“π°“√≥å ´÷Ë߇ªìπæƒμ‘°√√¡∑’Ë¡’§«“¡„°≈⇧’¬ßμàÕ
[10]
°“√®”·π°·∫∫®”≈Õß„π°“√»÷°…“‚√§«‘μ° ∑ƒ…Æ’°“√‡°‘¥‚√§„π§π
°—ß«≈„π —μ«å∑¥≈Õß “¡“√∂·∫àßÕÕ°‡ªìπ 1) Condi- EPM ‡ªìπ·∫∫®”≈Õß∑“ßæƒμ‘°√√¡¢Õß‚√§
tioned response ‡™àπ Vogel conflict, Four-plate «‘μ°°—ß«≈∑’Ëπ—°«‘®—¬π‘¬¡„™â°—π¡“°∑’Ë ÿ¥ ‡√‘Ë¡π”¡“
[11]
test, Geller-Seifter conflict ·≈– 2) Uncondi- ∑¥ Õ∫„πÀπŸ·√∑‡ªìπ§√—Èß·√°„πªï 1985 ·∫∫
tioned response ‡™àπ Elevated Plus Maze ®”≈Õßπ’È¡’≈—°…≥–‡ªìπ‡§√◊ËÕßÀ¡“¬∫«° ´÷Ëߪ√–°Õ∫
(EPM), Dark/Light Box (DLB) ·≈– Open Field ‰ª¥â«¬·¢πªî¥∑’ËÀ—πÀπⓇ¢â“À“°—π 2 ¥â“π ·≈–·¢π
Test (OFT) —μ«å∑¥≈Õß®–· ¥ßªØ‘°‘√‘¬“°“√À≈∫ ‡ªî¥Õ’° 2 ¥â“π (√Ÿª∑’Ë 1A) μ—«¢Õß·∫∫®”≈Õß®–¬°
